Eidos Therapeutics Inc. (EIDX) 13D/13G Filings for BridgeBio Pharma, Inc. (BBIO)

Eidos Therapeutics Inc. 13D and 13G filings for BridgeBio Pharma, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2021-01-26
4:23 pm
Sale		 2021-01-26 13D BridgeBio Pharma, Inc.
BBIO		 Eidos Therapeutics Inc.
EIDX		 0
0.000%		 -44,651,896decrease
(Position Closed)		 Filing
2020-10-15
4:17 pm
Purchase		 2020-10-05 13D BridgeBio Pharma, Inc.
BBIO		 Eidos Therapeutics Inc.
EIDX		 44,651,896
36.400%		 44,651,896increase
(New Position)		 Filing